Related Experiment Video
Updated: Jun 15, 2026
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing
Abstract:
Chemotherapeutics (e.g., aurora kinase inhibitors) designed to target proliferative cells are often nonspecific for tumor cells as normal cycling cells are also susceptible. Indeed, one of the major dose-limiting toxicities of aurora kinase inhibitors is a dangerous depletion of neutrophils in patients. In this study we proposed a strategy to selectively target p53 mutant cells while sparing normal ones. The strategy is based on the understanding that normal cells have an intact p53 pathway but not tumor cells carrying p53 mutations. Nongenotoxic activation of p53 using nutlin led to a reversible activation of G1 and G2 arrest in normal cells, which prevents them from entering mitosis, thus protecting them from the side effects of aurora kinase inhibition (VX-680), namely endoreduplication and apoptosis. Cells carrying mutant p53 are selectively killed by the nutlin/VX-680 combination, whereas p53 wild-type cells retain their proliferative capacity. The major implications drawn from these results are: (1) reversible nongenotoxic activation of p53 may be used as a strategy for the chemoprotection of normal tissues, and (2) aurora kinase inhibitors may have alleviated side effects when used in combination with nutlin-like inhibitors. We highlight the distinct roles of p53 and p73 in mediating the cellular responses to VX-680 and suggest that dual protection by p53 and p73 are needed to guard against endoreduplication and polyploidy.
Insights
This study shows that activating the p53 pathway with nutlin can protect normal cells from chemotherapy side effects. This combination therapy selectively kills cancer cells with p53 mutations while sparing healthy cells.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Chemotherapeutics like aurora kinase inhibitors lack specificity, harming normal cycling cells and causing toxicities such as neutropenia.
- Tumor cells often harbor p53 mutations, disrupting the p53 pathway, while normal cells possess an intact p53 pathway.
Purpose of the Study:
- To develop a strategy for selectively targeting p53-mutant cancer cells while protecting normal tissues from chemotherapy-induced damage.
- To investigate the potential of combining p53 activation with aurora kinase inhibition for cancer therapy.
Main Methods:
- Utilized nutlin, a nongenotoxic compound, to activate the p53 pathway in normal cells.
- Administered aurora kinase inhibitor VX-680 in combination with nutlin.
- Assessed cellular responses including G1/G2 arrest, endoreduplication, apoptosis, and proliferation in both normal and p53-mutant cells.
Main Results:
- Nongenotoxic p53 activation via nutlin induced reversible G1 and G2 arrest in normal cells, preventing mitosis and protecting against VX-680 side effects.
- The combination of nutlin and VX-680 selectively killed p53-mutant cancer cells.
- Normal cells with wild-type p53 retained their proliferative capacity, demonstrating chemoprotection.
Conclusions:
- Reversible, nongenotoxic p53 activation can serve as a chemoprotective strategy for normal tissues during cancer treatment.
- Combining aurora kinase inhibitors with nutlin-like compounds may mitigate treatment-related side effects.
- Distinct roles of p53 and p73 in cellular response to VX-680 suggest dual protection is necessary against endoreduplication and polyploidy.
Related Concept Videos
02:23Abnormal Proliferation
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:16In-vitro Mutagenesis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...